Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATSA trial of long-acting somatostatin analogue use during PRRT
NL-OMON58930Phase 4Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Jun 2024
- Modality
- Peptides, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 4, open-label trial of octreotide and lutetium (177Lu) oxodotreotide in apudoma (NET) (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Absorbed dose in target lesions. Started Jun 2024; status: recruiting.
02
Drugs
octreotidelutetium (177Lu) oxodotreotide
03
Conditions
apudoma (NET)
Beyond the preview
Go deeper on NL-OMON58930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58930.